Dr. David Tran is the principle investigator, faculty sponsor, and/or study chair of the following investigator-initiated clinical trials:
PRECISION: A Phase II Study of the NovoTTF-100A System, Enhanced by Genomic Analysis to Identify the Genetic Signature of Response in the Treatment of Recurrent Glioblastoma.
PROGRESS: A Phase I and Open Label, Randomized, Controlled Phase II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 (PD-1 inhibitor) in combination with MRI-guided Laser Ablation in Recurrent Malignant Gliomas.
PULSED AVASTIN: Phase 2, Single arm, historically controlled study testing the combination of TTFields and Pulsed Bevacizumab treatment in patients with bevacizumab-refractory recurrent GBM.
A Dose Finding Phase 1 of Sarilumab plus Capecitabine in HER2/neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab plus Capecitabine in Stage I-III Triple Negative Breast Cancer with High-Risk Residual
2-THE-TOP: Phase 2, single arm, historically controlled study testing the combination of adjuvant Temozolomide plus TTFields plus Pembrolizumab in patients with newly diagnosed glioblastoma.